Who founded Holobiome, Inc.?

Holobiome, Inc. was founded by Philip Strandwitz, Kim Lewis, Mike La Fleur in 2015.

Who are Holobiome, Inc.'s investors?

Holobiome, Inc.'s investors include Able Partners, Astanor Ventures, Bantam Group, Deep Future, Healthtech Capital, iSelect Fund, Pace Ventures, Service Provider Capital and 3 more.

How much funding has Holobiome, Inc. raised?

Holobiome, Inc. has disclosed $17.5M raised across 4 rounds.

Where is Holobiome, Inc. headquartered?

Holobiome, Inc. is headquartered in Boston, US.

Holobiome, Inc.

Boston, US · Founded 2015 · Delaware corporation · 19 employees on LinkedIn · 11 known investors

Find your way into Holobiome, Inc.

Each arrow is one introduction. Sign up to fill in the first one.

124 people can intro you to Philip

Ask Saunaz Moradi to introduce you to Philip Strandwitz

You →Saunaz · together at Northeastern University →Philip

Your email: who you already know at Holobiome, Inc., and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Holobiome, Inc. team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Holobiome discovers and develops therapies derived from the human gut microbiome, working to translate microbiome science into probiotics and targeted treatments for whole-body health. The company was founded by research scientists from Northeastern University.

AI & Machine Learning Biotech Healthtech Longevity

Founders & leadership

Holobiome, Inc. was founded in 2015 by Philip Strandwitz, Kim Lewis, and Mike La Fleur.

Philip Strandwitz Co-founder and CEOPhilip Strandwitz is co-founder and CEO of Holobiome, which develops therapies and probiotics derived from the human gut microbiome. He was trained as a research scientist, including work at Northeastern University where he helped found the company.

Kim LewisCo-founder, Director

Mike La FleurPresident, Co-founder, Director

Michael LaFleurExecutive

Board

Joan LaRovere Board MemberOperating Partner at iSelect Fund

Iain ChessellBoard director

Investors · 11

Able Partnerslisted by Able PartnersNew York · $500K – $3M

How we know: the VCSheet dataset · Not right? Tell us

Astanor Ventureslisted by Astanor VenturesLuxembourg, Grand-Duchy Of Luxembourg

How we know: Astanor Ventures's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Bantam Grouplisted by Bantam GroupWestwood

How we know: the VCSheet dataset · Not right? Tell us

Deep Futurelisted by Deep FutureSeattlevia Pablos Holman · inferred

How we know: Deep Future's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Healthtech Capitallisted by Healthtech CapitalSilicon Valley

How we know: Healthtech Capital's portfolio page · Not right? Tell us

iSelect Fundlisted by iSelect FundSt. Louis · $250K – $2M

How we know: iSelect Fund's portfolio page · funding news · press coverage · Not right? Tell us

Pace Ventureslisted by Pace VenturesBerlin · $550K – $1.6Mvia Marius Swart · inferred

How we know: funding news · press coverage · Not right? Tell us

Service Provider Capitallisted by Service Provider CapitalVail

How we know: the VCSheet dataset · Not right? Tell us

Valor Equity Partnerslisted by Valor Equity PartnersChicago

How we know: Valor Equity Partners's portfolio page · funding news · press coverage · Not right? Tell us

AlexandriareportedPasadena

How we know: funding news · press coverage · Not right? Tell us

SkyRiver VenturesreportedLexington

How we know: funding news · press coverage · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$17.5M disclosed across 4 rounds · 2018–2025

▶$10MraisedJul 2026 · 5 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Philip StrandwitzExecutive Officer, Director
Iain ChessellDirector
Joan LaRovereDirector
Michael LaFleurExecutive Officer

Offering amount: $10M
Amount sold: $10M
First sale: Dec 2025
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$6.6MraisedMar 2024 · 19 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Philip StrandwitzExecutive Officer, Director
Iain ChessellDirector
Michael LaFleurExecutive Officer
Joan LaRovereDirector

Offering amount: $9.4M
Amount sold: $6.6M
First sale: Mar 2024
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$300KraisedFeb 2021 · 2 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Michael LafleurDirector
Kim LewisDirector
Philip StrandwitzExecutive Officer, Director
Ian ChessellDirector

Offering amount: $2M
Amount sold: $300K
First sale: Feb 2021
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$625KraisedDec 2018 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Phil StrandwitzExecutive Officer, Director
Michael LafleurDirector
Kim LewisDirector
Iain ChessellDirector

Offering amount: $1.3M
Amount sold: $625K
First sale: Dec 2018
Incorporated: Corporation, Delaware, 2015
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 4

BIOHMBIOHM sells probiotic supplements and at-home gut test kits that analyze the microbiome, with results reviewed by a microbiome-trained registered nutritionist who provides personalized diet and supplement recommendations. Its formula combines bacteria, fungi, and a digestive enzyme intended to support digestive health.

Viome Life SciencesViome offers at-home tests that analyze the gut and oral microbiome plus cellular blood samples using mRNA/metatranscriptomic sequencing, returning 70+ health scores (including biological age and inflammation) and personalized food and supplement recommendations. The direct-to-consumer service, analyzed in a CLIA-certified lab, is aimed at individuals seeking insights into digestion, metabolism, and overall wellness.

BiomeSenseBiomeSense builds an AI-enabled platform combining hardware (GutLab) and bioinformatics (MetaBiome) to continuously generate and analyze gut microbiome data. It serves scientists, institutions, and companies conducting clinical research on the microbiome for personalized biomarker discovery and product development.

OpenBiomeOpenBiome Foundation advances microbiome-targeted therapies for serious conditions like Clostridioides difficile through partnerships, innovation funding, and open-access research tools. The organization works to expand patient access to microbiome treatments while accelerating scientific discovery in the field.

Companies working in the same space as Holobiome, Inc..

Frequently asked questions

What does Holobiome, Inc. do?: Holobiome discovers and develops therapies derived from the human gut microbiome, working to translate microbiome science into probiotics and targeted treatments for whole-body health. The company was founded by research scientists from Northeastern University.
Who founded Holobiome, Inc.?: Holobiome, Inc. was founded by Philip Strandwitz, Kim Lewis, Mike La Fleur in 2015.
Who are Holobiome, Inc.'s investors?: Holobiome, Inc.'s investors include Able Partners, Astanor Ventures, Bantam Group, Deep Future, Healthtech Capital, iSelect Fund, Pace Ventures, Service Provider Capital and 3 more.
How much funding has Holobiome, Inc. raised?: Holobiome, Inc. has disclosed $17.5M raised across 4 rounds.
Where is Holobiome, Inc. headquartered?: Holobiome, Inc. is headquartered in Boston, US.